Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Short-term Investments: 2009-2024

Historic Short-term Investments for Cytokinetics (CYTK) over the last 15 years, with Dec 2024 value amounting to $981.2 million.

  • Cytokinetics' Short-term Investments fell 23.60% to $737.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $737.1 million, marking a year-over-year decrease of 23.60%. This contributed to the annual value of $981.2 million for FY2024, which is 95.53% up from last year.
  • Latest data reveals that Cytokinetics reported Short-term Investments of $981.2 million as of FY2024, which was up 95.53% from $501.8 million recorded in FY2023.
  • In the past 5 years, Cytokinetics' Short-term Investments ranged from a high of $981.2 million in FY2024 and a low of $359.0 million during FY2021.
  • Moreover, its 3-year median value for Short-term Investments was $717.0 million (2022), whereas its average is $733.3 million.
  • Per our database at Business Quant, Cytokinetics' Short-term Investments spiked by 101.97% in 2020 and then slumped by 30.01% in 2023.
  • Yearly analysis of 5 years shows Cytokinetics' Short-term Investments stood at $381.1 million in 2020, then decreased by 5.80% to $359.0 million in 2021, then skyrocketed by 99.74% to $717.0 million in 2022, then crashed by 30.01% to $501.8 million in 2023, then soared by 95.53% to $981.2 million in 2024.